{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Design": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Participants": {
        "score": 2,
        "evidence": "patients undergoing thoracofemoral bypass for severe aortoiliac occlusive disease"
      },
      "Intervention": {
        "score": 2,
        "evidence": "The BARD IMPRA expanded polytetrafluoroethylene vascular graft was employed for thoracobifemoral bypass surgery."
      },
      "Objective": {
        "score": 1,
        "evidence": "This analysis aims to scrutinize the 10-year experience and early outcomes of 90 patients who underwent thoracofemoral bypass as a primary procedure."
      },
      "Method_Outcome": {
        "score": 1,
        "evidence": "The primary indication was complete abdominal aorta obstruction at the renal artery level with an unsuitable site for aorta clamping."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "90 patients"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "Intraoperative and postoperative data were analyzed"
      },
      "Result_Outcome": {
        "score": 1,
        "evidence": "The 30-day mortality rate was 3.33% ( n =\u20093)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Major morbidities included graft occlusion in one patient, managed by embolectomy, and ascites in another patient, addressed conservatively."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 11,
    "max_score": 25
  },
  "model": "gpt-4o"
}